News -
Stock Information
Relmada Therapeutics is dedicated to reshaping the standard of care for central nervous system disorders.
Our lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in advanced clinical development for the treatment of major depressive disorder (MDD).
Data from the phase 2 trial with REL-1017 suggest rapid, robust, and sustained antidepressant effects with statistically significant improvements as compared to placebo on all tested efficacy measures (Fava 2022). The phase 2 study data also confirm the very favorable safety and tolerability profile of REL-1017 seen in phase 1 studies (Bernstein 2019). The U.S. Food and Drug Administration has granted Fast Track designations to REL-1017 for the treatment of MDD. The phase 3 Reliance clinical trial program is underway with Reliance II and Reliance OLS ongoing and an expected initiation of additional clinical evaluations.
News
Past events
Event - Mar 23, 2023 4:30 pm EDT
Q4 2022 Financial Results Conference Call
Read moreEvent - Nov 10, 2022 4:30 pm EDT
Q3 2022 Financial Results Conference Call
Read moreEvent - Aug 11, 2022 4:30 pm EDT
Q2 2022 Financial Results Conference Call
Read moreEvent - Jun 14, 2022 10:40 am PDT
Goldman Sachs 43rd Annual Global Healthcare Conference
Read moreEvent - Jun 8, 2022 4:00 pm EDT
2022 Jefferies Global Healthcare Conference
Read moreEvent - May 31 – Jun 3, 2022
American Society of Clinical Psychopharmacology 2022 Annual Meeting
Event - May 25, 2022 9:30 am EDT
2022 Annual Meeting of Stockholders
Read moreEvent - May 5, 2022 4:30 pm EDT